Overman, M. J., Kopetz, S., McDermott, R. S., Leach, J., Lonardi, S., Lenz, H.-J., … Andre, T. (2016). Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. In Journal of Clinical Oncology (Vol. 34, pp. 3501–3501). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2016.34.15_suppl.3501

Overman, Michael J., Scott Kopetz, Raymond S. McDermott, Joseph Leach, Sara Lonardi, Heinz-Josef Lenz, Michael A. Morse, et al. “Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.” In Journal of Clinical Oncology, 34:3501–3501. American Society of Clinical Oncology (ASCO), 2016. https://doi.org/10.1200/jco.2016.34.15_suppl.3501.

Overman MJ, Kopetz S, McDermott RS, Leach J, Lonardi S, Lenz H-J, et al. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 3501–3501.

Overman, Michael J., et al. “Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results.” Journal of Clinical Oncology, vol. 34, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2016, pp. 3501–3501. Crossref, doi:10.1200/jco.2016.34.15_suppl.3501.

Overman MJ, Kopetz S, McDermott RS, Leach J, Lonardi S, Lenz H-J, Morse MA, Desai J, Hill A, Axelson MD, Moss RA, Lin C-S, Goldberg M, Andre T. Nivolumab ± ipilimumab in treatment (tx) of patients (pts) with metastatic colorectal cancer (mCRC) with and without high microsatellite instability (MSI-H): CheckMate-142 interim results. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2016. p. 3501–3501.